IO Biotech, Inc. (IOBT) financial statements (2022 and earlier)

Company profile

Business Address OLE MAALOES VEH 3
COPENHAGEN, 2200
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments211,53145,477
Cash and cash equivalents211,53145,477
Receivables1,250407
Prepaid expense3,346362
Deferred costs 2,413
Other undisclosed current assets5,6113,334
Total current assets:221,73851,993
Noncurrent Assets
Restricted cash and investments268 
Other noncurrent assets282 
Other undisclosed noncurrent assets 45
Total noncurrent assets:55045
TOTAL ASSETS:222,28852,038
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,4444,499
Accounts payable3,9282,166
Accrued liabilities1,4891,795
Employee-related liabilities1,027538
Other undisclosed current liabilities3,86129,287
Total current liabilities:10,30533,786
Noncurrent Liabilities
Liabilities, other than long-term debt59 
Other liabilities59 
Total noncurrent liabilities:59 
Total liabilities:10,36433,786
Stockholders' equity
Stockholders' equity attributable to parent, including:211,924(82,637)
Common stock29 
Additional paid in capital319,6651,602
Accumulated other comprehensive income (loss)(1,489)705
Accumulated deficit(106,281)(84,972)
Other undisclosed stockholders' equity attributable to parent 28
Other undisclosed stockholders' equity 100,889
Total stockholders' equity:211,92418,252
TOTAL LIABILITIES AND EQUITY:222,28852,038

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
Operating expenses(21,395)(7,042)
Operating loss:(21,395)(7,042)
Nonoperating income1542,580
Interest and debt expense(151)(67)
Loss from continuing operations before equity method investments, income taxes:(21,392)(4,529)
Other undisclosed income from continuing operations before income taxes361 
Loss from continuing operations before income taxes:(21,031)(4,529)
Other undisclosed loss from continuing operations(68) 
Loss before gain (loss) on sale of properties:(21,099)(4,529)
Other undisclosed net loss(210) 
Net loss:(21,309)(4,529)
Other undisclosed net income attributable to parent 67
Net loss attributable to parent:(21,309)(4,462)
Preferred stock dividends and other adjustments(1,102)(2,073)
Net loss available to common stockholders, diluted:(22,411)(6,535)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
Net loss:(21,309)(4,529)
Comprehensive loss:(21,309)(4,529)
Other undisclosed comprehensive loss, net of tax, attributable to parent(2,194)(614)
Comprehensive loss, net of tax, attributable to parent:(23,503)(5,143)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: